Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Prepaid Assets (2022 - 2025)

Historic Prepaid Assets for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to $1.5 million.

  • Orchestra BioMed Holdings' Prepaid Assets rose 1979.66% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.5 million, marking a year-over-year increase of 1979.66%. This contributed to the annual value of $2.1 million for FY2024, which is 6436.42% up from last year.
  • Orchestra BioMed Holdings' Prepaid Assets amounted to $1.5 million in Q3 2025, which was up 1979.66% from $1.7 million recorded in Q2 2025.
  • In the past 5 years, Orchestra BioMed Holdings' Prepaid Assets ranged from a high of $2.3 million in Q1 2023 and a low of $36417.0 during Q2 2022
  • In the last 4 years, Orchestra BioMed Holdings' Prepaid Assets had a median value of $1.3 million in 2023 and averaged $1.2 million.
  • As far as peak fluctuations go, Orchestra BioMed Holdings' Prepaid Assets soared by 393108.44% in 2023, and later plummeted by 4831.12% in 2024.
  • Orchestra BioMed Holdings' Prepaid Assets (Quarter) stood at $533000.0 in 2022, then surged by 139.02% to $1.3 million in 2023, then skyrocketed by 64.36% to $2.1 million in 2024, then decreased by 26.89% to $1.5 million in 2025.
  • Its Prepaid Assets stands at $1.5 million for Q3 2025, versus $1.7 million for Q2 2025 and $1.8 million for Q1 2025.